-
Ciloa SAS secures €6.5m to advance lead candidate APN-sEV into clinical development
09 Jul 2025 08:11 GMT
… development of its lead candidate, APN-sEV, for the treatment … of retinopathy (age-related macular degeneration, retinopathy of prematurity, and … more holistic approach to treating metabolic disorders.”
The funding … a Phase I clinical trial in 2027, followed by …
-
Phase 3 PHOENIX trial for oral GA treatment completes enrollment
08 Jul 2025 20:53 GMT
… 3 trial for this oral medication. This trial will … in dry age-related macular degeneration (AMD).1
The study … through late-stage development and look forward … Drug Administration (FDA) has granted Breakthrough Therapy Designation for the company’s treatment …
-
First Patient Dosed in Phase 1 Trial of PulseSight Therapeutics’ PST-611 for Dry AMD/GA
08 Jul 2025 20:52 GMT
… trial (PST-611-CT1), marking a key milestone in the clinical development … 611, for dry age-related macular degeneration (AMD) and geographic atrophy … vectorized therapy designed to treat dry AMD/GA … to become a major treatment option for these patients.” …
-
Instant Coffee and Genetics May Raise Risk of Dry Age-Related Macular Degeneration: Study
07 Jul 2025 22:03 GMT
… findings support the development of personalized age-related macular degeneration prevention strategies. Clinicians … contribute to age-related macular degeneration prevention and treatment.
Reference:
Jia, Q., Z …
-
PulseSight doses first subject in Phase I trial of dry AMD/GA therapy
08 Jul 2025 13:46 GMT
… 611, targeting dry age-related macular degeneration (AMD) and geographic atrophy … the subsequent Phase IIa trial.
The company expects to … also involved in the trial.
Dysregulation of iron homeostasis … patients’ compliance with the treatment. Once the safety and …
-
Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP
08 Jul 2025 12:00 GMT
… VISTA trial evaluating laru-zova for the treatment … S. Food and Drug Administration (FDA), Priority Medicines (PRIME … -stage clinical development candidate to treat XLRP and … two preclinical programs targeting dry age-related macular degeneration …
-
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
07 Jul 2025 12:22 GMT
… treatment2,9
“At LumiThera, we have been committed to developing … approach for detecting, treating, and monitoring retinal … Drug Administration (FDA) has authorized marketing of the PBM device treatment … with dry age-related macular degeneration (AMD) (LIGHTSITE …
-
Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up
08 Jul 2025 10:35 GMT
… deposition, which can develop into a subretinal … VEGF) drugs has significantly improved the treatment results … the nonrandomized controlled trial FIREFLEYE next. JAMA … Treat-and-extend regimens for the management of neovascular age-related macular degeneration …
-
Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium
08 Jul 2025 02:20 GMT
… accepted for treatment of adults with wet age-related macular degeneration.
Osimertinib … to AstraZeneca’s osimertinib treatment for treatment of lung cancer … Recommends Eladynos (abaloparatide) for Treating Osteoporosis in Postmenopausal Women. Press …
-
Wet AMD Pipeline Appears Robust With 60+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight
08 Jul 2025 01:19 GMT
… drug is been registered for the treatment of Wet Age-Related Macular Degeneration … treatments, ranibizumab (ShORe trial) and aflibercept (COAST trial … Drugs under development … Pharmaceuticals, Kyowa Kirin, Exonate and others.
Wet Age-related Macular Degeneration …
About
© 1995-2025